Is more the better?—cetuximab in non-small cell lung cancer patients

Lung cancer treatment has experienced a major change in the last decades with the identification of differential molecular traits to guide the therapeutic decisions. This strategy has led to classify patients in lung cancer subsets with differential prognosis and treatment approaches. However, there is still a substantial proportion of patients in whom no molecular marker is found and upfront chemotherapy still remains their best option.